Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05. September 2019 16:05 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction
09. August 2019 08:00 ET
|
Aquinox Pharmaceuticals, Inc.
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company...
Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
07. August 2019 08:00 ET
|
Aquinox Pharmaceuticals, Inc.; Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement
06. August 2019 07:00 ET
|
Aquinox Pharmaceuticals, Inc.
• Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program,...
Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results
07. November 2018 09:15 ET
|
Aquinox Pharmaceuticals, Inc.
VANCOUVER, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to...
Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results
08. August 2018 06:15 ET
|
Aquinox Pharmaceuticals, Inc.
VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to...
Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome
27. Juni 2018 06:30 ET
|
Aquinox Pharmaceuticals, Inc.
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), today announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating...
Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS
11. Juni 2018 09:05 ET
|
Aquinox Pharmaceuticals, Inc.
- Trial Will Enroll Approximately 100 Male Subjects in the US and Canada - VANCOUVER, British Columbia, June 11, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a...
Aquinox to Present at 2018 UBS Global Healthcare Conference
16. Mai 2018 13:32 ET
|
Aquinox Pharmaceuticals, Inc.
VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug...
Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan
09. Mai 2018 21:00 ET
|
Aquinox Pharmaceuticals, Inc.
-Aquinox to Receive $25M in Upfront Payment, Potentially Over $100M in Additional Milestone Payments and Royalties- -Astellas to Obtain Development and Commercialization Rights to Rosiptor,...